ChAd155-RSV (GSK3389245A)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ChAd155-RSV (GSK3389245A), covering 2021-10-28 to 2021-10-28. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants [Phase 1, Phase 2]